dc.contributor.author | Rokhsartalab-Azar, S | |
dc.contributor.author | Shapouri, R | |
dc.contributor.author | Rahnema, M | |
dc.contributor.author | Najafzadeh, F | |
dc.contributor.author | Kianmehr, A | |
dc.date.accessioned | 2018-08-26T09:37:27Z | |
dc.date.available | 2018-08-26T09:37:27Z | |
dc.date.issued | 2015 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58105 | |
dc.description.abstract | Background and Objective: Escherichia coli O157:H7, an emerging pathogen, causes severe enteritis and the extraintestinal complication of hemolytic-uremic syndrome. The goal of this study was to evaluate the conjugate of E. coli O157: H7 lipopolysaccharide (LPS) with diphtheria toxoid (DT) as a candidate vaccine in mice model. Material and Methods: LPS from E. coli O157:H7 was extracted by hot phenol method and then detoxified. Purified LPS was coupled to DT with adipic acid dihydrazide (ADH) as a spacer and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) as a linker. The coupling molar ratio of LPS to DT was 3:1. Clinical evaluation of E. coli O157:H7 LPS-DT conjugate was also performed. Results: The conjugate was devoid of endotoxin activity and indicated 0.125 U/ml of D-LPS. Mice immunization with D-LPS DT conjugate elicited fourfold higher IgG antibody in comparison to D-LPS. Also, in vivo protection of mice with conjugate provided high protection against the LD<inf>50</inf> of E. coli O157:H7, which indicated a good correlation with the IgG titer. Conclusion: Our results showed that the suggested vaccine composed of E. coli O157:H7 LPS and DT had a significant potential to protect against E. coli infections. © 2015, Tehran University of Medical Science. All rights reserved. | |
dc.language.iso | English | |
dc.relation.ispartof | Iranian Journal of Microbiology | |
dc.subject | diphtheria vaccine | |
dc.subject | Escherichia coli vaccine | |
dc.subject | Escherichia coli01507:H7 lipopolysaccharide dipehtheria toxoid vaccine | |
dc.subject | Escherichia coli01507:H7 lipopolysaccharide vaccine | |
dc.subject | immunoglobulin G antibody | |
dc.subject | immunoglobulin M antibody | |
dc.subject | pyrogen | |
dc.subject | unclassified drug | |
dc.subject | animal experiment | |
dc.subject | Article | |
dc.subject | bactericidal activity | |
dc.subject | colony forming unit | |
dc.subject | controlled study | |
dc.subject | detoxification | |
dc.subject | enzyme linked immunosorbent assay | |
dc.subject | female | |
dc.subject | immunization | |
dc.subject | immunogenicity | |
dc.subject | lethal dose | |
dc.subject | Limulus lysate test | |
dc.subject | mouse | |
dc.subject | nonhuman | |
dc.subject | polyacrylamide gel electrophoresis | |
dc.subject | vaccine production | |
dc.subject | Escherichia coli | |
dc.subject | Escherichia coli O157:H- | |
dc.subject | Mus | |
dc.title | Synthesis, characterization and immunological properties of Escherichia coli 0157:H7 lipopolysaccharide- diphtheria toxoid conjugate vaccine | |
dc.type | Article | |
dc.citation.volume | 7 | |
dc.citation.issue | 3 | |
dc.citation.spage | 150 | |
dc.citation.epage | 155 | |
dc.citation.index | Scopus | |